# RECENT DEVELOPMENTS IN THE MUCOADHESIVE DRUG DELIVERY SYSTEM DOMAIN

**Abstract**

Mucoadhesive drug delivery systems have emerged as a promising approach to enhance the efficacy and specificity of drug administration. In recent years, significant advancements in this domain have expanded the possibilities of targeted drug delivery to mucosal surfaces, revolutionizing the Pharmaceutical field. The utilization of novel mucoadhesive polymers and nanoparticles has paved the way for controlled and sustained drug release, overcoming the limitations of conventional dosage forms. By exploiting the adhesive properties of these formulations, drug bioavailability has been substantially improved, while the extended residence time at the target site allows for optimized therapeutic outcomes. Such advancements have particularly proven beneficial for delivering a diverse range of therapeutics, including vaccines, peptides, proteins, and nucleic acids. Furthermore, the integration of advanced nanotechnology and bioengineering techniques has led to the development of mucoadhesive platforms with enhanced stability, biocompatibility, and tailored release profiles. Recent advancements in mucoadhesive drug delivery hold immense promise for personalized and targeted therapeutic interventions. The continuous evolution of this field is likely to result in more effective and patient-friendly drug delivery solutions, ultimately improving patient compliance and healthcare outcomes. By addressing the remaining challenges, mucoadhesive drug delivery can be expected to play a vital role in shaping the future of Pharmaceutical research and clinical practice. . This chapter aims to provide an overview of the recent developments in mucoadhesive drug delivery, highlighting key research findings and technological innovations.

**Keyword:** Mucoadhesive drug delivery system, mucoadhesive polymer, bioadhesive polymer, controlled release, bioavailability.

**Authors**

**Mayuri Phukan**
Department of Pharmaceutics
Pratiksha Institute of Pharmaceutical Sciences
Panikhaiti, Guwahati, Assam, India.

**Bitu Gogoi**
Department of Pharmaceutical Chemistry
NETES Institute of Pharmaceutical Science
Shantipur, Mirza, Guwahati, Assam, India.
bitugogoi2015@gmail.com

**Abhishek Parasar**
Department of Pharmaceutics
Pratiksha Institute of Pharmaceutical Sciences
Panikhaiti, Guwahati, Assam, India.

**Farida Pegu**
Department of Pharmacognosy
JB Institute of Pharmacy, Srimanta Sankaradeva University of Health Sciences, Guwahati, Assam, India.

# I. INTRODUCTION

The field of drug delivery has witnessed significant advancements over the years, aiming to improve therapeutic efficacy, reduce side effects, and enhance patient compliance. One such promising area of research is the development of mucoadhesive drug delivery systems. These specialized formulations have garnered considerable attention for their ability to adhere to the mucosal surfaces of various tissues, offering a unique and targeted approach to drug administration [1]. In recent years, significant strides have been made in understanding the intricate interactions between mucoadhesive polymers and mucosal tissues, leading to the design of more efficient and effective drug delivery systems. Researchers have explored various routes of administration, such as buccal, nasal, vaginal, and ocular, each offering unique advantages for specific therapeutic applications [2].

Mucoadhesive drug delivery systems have emerged as a promising area of research in the Pharmaceutical field, offering innovative solutions to various challenges associated with conventional drug delivery methods. The term "mucoadhesive" refers to the ability of these formulations to stick to the mucus layer, which is present on the surface of many mucosal tissues. These systems are designed to adhere to mucosal surfaces, providing targeted and localized drug delivery to specific tissues, such as those in the gastrointestinal tract, buccal cavity, nasal passages, vaginal tract, and ocular surfaces. The recent advancements in the mucoadhesive drug delivery system domain have garnered significant attention from researchers and healthcare professionals alike due to their potential to improve therapeutic outcomes, enhance patient compliance, and address unmet medical needs. Traditional drug delivery methods often encounter obstacles, such as poor drug bioavailability, rapid drug clearance, and systemic side effects. Mucoadhesive drug delivery systems offer a range of advantages over conventional approaches by extending the residence time of drugs on mucosal surfaces, allowing for sustained drug release and enhanced drug absorption. These systems have the potential to revolutionize the way medications are administered, offering non-invasive and patient-friendly alternatives that can be particularly beneficial for pediatric, geriatric, and other vulnerable patient populations.

In this rapidly evolving domain, researchers are exploring novel biomaterials, polymers, and nanoparticles to design mucoadhesive drug delivery systems with improved performance and efficiency. The development of these advanced formulations requires a deep understanding of the Physicochemical properties of mucoadhesive polymers, drug release kinetics, and the biological interactions occurring at the mucosal interface.

Moreover, the recent developments in mucoadhesive drug delivery systems have opened up new possibilities for targeted drug delivery, enabling therapies for diseases that require localized drug action, such as mucosal infections and gastrointestinal disorders. Additionally, the potential to reduce systemic drug exposure can significantly minimize adverse effects associated with certain medications, providing safer and more tolerable treatment options.

## 1. Key Characteristics and Significance of Mucoadhesive Drug Delivery Systems:

- **Improved Adhesion**: Mucoadhesive systems contain specific adhesive agents that can attach to the mucosal surfaces, forming a strong and prolonged bond. This

 

adhesion ensures that the drug remains in contact with the mucosa for an extended period, enhancing drug absorption and reducing the risk of drug removal through natural clearance mechanisms. [3]

- **Localized Drug Release:** By maintaining drug contact with the mucosal surface, mucoadhesive systems enable localized drug release at the target site. This feature is particularly valuable when treating conditions in specific areas, such as gastrointestinal ulcers, oral infections, or vaginal disorders. One such approached is delivery of mucoadhesive drug in buccal mucosa. [4]

- **Enhanced Bioavailability:** Mucoadhesive systems can improve drug absorption across mucosal barriers, where some drugs may have limited bioavailability due to poor permeability. By increasing the residence time of drugs on the mucosal surface and potentially bypassing the first-pass metabolism, mucoadhesive systems can enhance drug absorption and therapeutic efficacy. [1], [2].

- **Minimization of Systemic Side Effects:** Targeted drug delivery with mucoadhesive systems allows for a reduction in the systemic exposure of drugs, leading to a lower risk of systemic side effects. This is especially relevant for drugs with a narrow therapeutic index or those known to cause adverse effects in other organs or tissues. [5]

- **Patient Convenience and Compliance:** Mucoadhesive drug delivery systems can offer convenient and patient-friendly administration methods. For example, buccal adhesive patches or gels can be applied to the inner cheek, providing a non-invasive and painless alternative to traditional oral drug administration. This can lead to improved patient compliance and better treatment outcomes. [6], [7]

- **Potential for Prolonged Action:** Some mucoadhesive systems can be designed to release drugs in a controlled and sustained manner, leading to a prolonged therapeutic effect. This is especially beneficial for drugs requiring long-term treatment or those with short half-lives. [8]

- **Versatility and Applicability:** Mucoadhesive drug delivery systems can be adapted for various routes of administration, including oral, nasal, buccal, vaginal, and ocular, making them versatile for a wide range of therapeutic applications. [1]

- **Exploring Novel Biomaterials:** Recent developments in the mucoadhesive drug delivery field often involve the exploration of new biomaterials, polymers, and nanoparticles. Understanding the properties and behavior of these materials can have broader implications beyond drug delivery, such as in tissue engineering and regenerative medicine.

## 2. Types of Mucoadhesive Drug Delivery Systems

- **Tablets and Patches:** These dosage forms are designed to adhere to the mucosal surface, such as the buccal cavity or sublingual region. They gradually release the drug, allowing for sustained and controlled drug delivery.

 

- **Gels and Ointments:** Mucoadhesive gels and ointments are applied topically to mucosal surfaces. They provide a localized effect and can be used in various applications, such as oral, nasal, vaginal, or rectal drug delivery.

- **Microspheres and Nanoparticles:** These are colloidal drug delivery systems that incorporate mucoadhesive polymers. They can be administered through different routes and offer sustained drug release.

- **Films and Strips:** Mucoadhesive films and strips are thin, flexible sheets that adhere to the mucosal surface. They can be used in various applications, including buccal, sublingual, and vaginal drug delivery.

- **Nanogels:** These are nanoscale hydro gel-based systems that can be loaded with drugs for targeted delivery to mucosal tissues.

Mucoadhesive drug delivery systems have shown promise in improving drug delivery efficiency for various therapeutic applications. However, the selection of appropriate mucoadhesive polymers, formulation techniques, and specific mucosal sites remains crucial to ensure optimal drug delivery performance. Additionally, research in this field is ongoing, and continuous advancements are expected to further refine these systems and expand their therapeutic potential. This system play a crucial role in targeted drug delivery by improving drug adhesion, enhancing drug bioavailability, reducing systemic side effects, and providing localized drug release at specific mucosal sites. Their versatility and potential for sustained drug action make them promising candidates for improving therapeutic outcomes and patient experiences in various medical conditions.

## II. INNOVATIVE MUCOADHESIVE DRUG DELIVERY SYSTEM

1. **Hydrogels as Mucoadhesive Platforms:** Hydrogels are three-dimensional cross-linked polymer networks that can absorb and retain large amounts of water. They have gained significant attention as mucoadhesive platforms in various fields, including drug delivery, tissue engineering, and biomedical applications. Mucoadhesion refers to the ability of a material to adhere to mucus membranes, such as those found in the gastrointestinal tract, nasal passages, and vaginal mucosa [12].

- **Formulation of Hydrogels as Mucoadhesive Platforms:** Hydrogels are polymer networks with hydroPhilic properties. Although they are typically made from hydroPhilic monomers, hydroPhobic monomers are occasionally used to tailor their properties for specific applications. Hydrogels can be derived from synthetic or natural polymers. Synthetic polymers are hydroPhobic and exhibit greater chemical strength than natural polymers, leading to slower degradation but increased durability. Achieving a balance between these opposing properties is crucial through optimal design [13]. This balance can also be achieved in hydrogels based on natural polymers if they possess appropriate functional groups or have been modified with radically polymerizable groups [14]

 

The preparation of hydrogels involves three essential components: monomer, initiator, and cross-linker. To regulate the heat of polymerization and achieve desired hydrogel properties, diluents like water or other aqueous solutions can be employed. Subsequently, the hydrogel mass must undergo washing to eliminate impurities remaining from the preparation process, such as non-reacted monomer, initiators, cross-linkers, and undesired by-products resulting from side reactions.

- **Applications of Mucoadhesive Hydrogels**

  - **Drug Delivery:** One of the most significant applications of mucoadhesive hydrogels is in drug delivery. By adhering to the mucus membranes, these hydrogels can extend the residence time of drugs at the target site, leading to improved therapeutic outcomes. They are particularly useful for delivering drugs to the gastrointestinal tract and nasal passages.
  - **Wound Dressings:** Mucoadhesive hydrogels can be used as wound dressings that adhere to the wound site, providing a moist environment that promotes wound healing and prevents microbial infections.
  - **Vaginal Drug Delivery:** Mucoadhesive hydrogels have been investigated for vaginal drug delivery, such as in the case of contraceptives, antifungals, and treatments for sexually transmitted infections.
  - **Ophthalmic Applications:** In oPhthalmology, mucoadhesive hydrogels have been explored for ocular drug delivery, including providing sustained drug release to the cornea and conjunctiva.
  - **Tissue Engineering:** These hydrogels can be employed as scaffolds for tissue engineering applications, supporting cell growth and tissue regeneration.
  - **Oral Care Products:** Mucoadhesive hydrogels can be incorporated into oral care products, such as toothpaste or mouthwashes, to prolong contact with oral mucosa and enhance the therapeutic effects of active ingredients.[15,16]

## 2. Mucoadhesive Nanoparticles and Microparticles

- **Formulation of Mucoadhesive Nanoparticles**: Formulation approaches for mucoadhesive nanoparticles involve techniques to design nanoparticles that can adhere to the mucosal surfaces for improved drug delivery, targeting, or localized therapy. Mucoadhesive nanoparticles aim to prolong residence time, increase drug absorption, and enhance therapeutic efficacy. Here are some common formulation approaches for mucoadhesive nanoparticles:

  - **Polymer Selection:** Choosing suitable polymers with mucoadhesive properties is essential. Natural polymers like chitosan, alginate, and hyaluronic acid, as well as synthetic polymers like poly(acrylic acid) and poly(vinyl alcohol), are often used due to their ability to interact with mucosal surfaces.
  - **Surface Modification:** Surface functionalization of nanoparticles with mucoadhesive ligands, such as lectins or thiolated polymers, enhances their mucoadhesive properties. Ligands can specifically interact with mucin proteins in the mucus layer.
  - **Nanoparticle Size and Shape:** Particle size and shape play a crucial role in mucoadhesion. Nanoparticles with appropriate size (typically in the range of 100-

 

500 nm) have better interactions with mucus, and specific shapes like nanorods or nanosPheres can improve mucoadhesion.

- **Ionic Gelation:** Ionic gelation involves the formation of nanoparticles through electrostatic interactions between oppositely charged polymers. For example, chitosan nanoparticles can be formed by ionic gelation with polyanions like tripolyPhosPhate or sodium alginate.
- **Emulsion Cross-linking:** In this approach, an emulsion of drug and polymer is prepared, followed by cross-linking of the polymer to form nanoparticles. It enables encapsulation of hydroPhobic drugs in the nanoparticles' core.
- **Nanoprecipitation:** Nanoparticles can be formed through the precipitation of a polymer from a solvent using an antisolvent. This approach is widely used for drug-loaded polymeric nanoparticles.
- **Layer-by-Layer Assembly:** Mucoadhesive nanoparticles can be prepared through layer-by-layer assembly of polyelectrolytes, where each layer provides specific functionalities, including mucoadhesion.
- **Mucoadhesive Hydrogel Nanoparticles:** Incorporating mucoadhesive nanoparticles into hydrogel matrices can further enhance their mucoadhesive properties and sustained drug release.
- **Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs):** SLNs and NLCs can be formulated with mucoadhesive polymers, improving their interaction with mucosal surfaces and providing controlled drug release.
- **In Situ Gelling Nanoparticles:** Nanoparticles can be designed to undergo gelation in situ upon administration to mucosal surfaces. These thermosensitive or Ph-sensitive nanoparticles can provide sustained drug release at the target site.[15,17,18,19]

- **Formulation Approaches of Mucoadhesive Micro Particle:** Formulation approaches for mucoadhesive microparticles involve techniques to design microparticles that can adhere to mucosal surfaces for localized drug delivery, extended residence time, and improved therapeutic efficacy. Mucoadhesive microparticles offer several advantages, including sustained drug release, reduced dosing frequency, and targeted drug delivery to specific mucosal sites. Here are some common formulation approaches for mucoadhesive microparticles:

  - **Polymer Selection:** Choosing appropriate mucoadhesive polymers is crucial. Natural polymers such as chitosan, alginate, hyaluronic acid, and cellulose derivatives are often used due to their inherent mucoadhesive properties.
  - **Emulsion-Solvent Evaporation:** This method involves dissolving the drug and polymer(s) in a water-immiscible organic solvent to form an emulsion. The emulsion is then added to an aqueous Phase containing a surfactant, and the solvent is allowed to evaporate, leading to the formation of microparticles.
  - **Spray Drying:** In this approach, a drug-polymer solution is atomized into fine droplets, which are then dried rapidly using hot air, resulting in the formation of microparticles.
  - **Coacervation:** Coacervation is a Phase separation technique where two oppositely charged polymers are mixed in a solution. Upon Phase separation, a coacervate Phase forms, which can be further solidified into microparticles.

 

- **Ionotropic Gelation:** This method involves crosslinking of polymers by the addition of counterions. For instance, alginate microparticles can be formed by adding calcium ions to an alginate solution.
- **In Situ Gelation:** Microparticles can be designed to undergo gelation in situ upon administration to mucosal surfaces. These thermosensitive or Ph-sensitive microparticles can provide sustained drug release at the target site.
- **Hot Melt Extrusion:** Hot melt extrusion is a continuous manufacturing process where the drug and polymers are melted, mixed, and then extruded to form microparticles.
- **Microfluidics:** Microfluidic techniques can be employed to precisely control the size and morPhology of mucoadhesive microparticles by manipulating the flow of materials in microchannels.
- **Electrohydrodynamic Atomization (EHDA):** EHDA uses an electric field to create droplets from a polymer solution, leading to the formation of mucoadhesive microparticles.
- **Surface Modification:** Surface functionalization of microparticles with mucoadhesive ligands can further enhance their adhesion to mucosal surfaces.[24-26]

## 3. Mucoadhesive Patches and Films

- **Formulation of Mucoadhesive Patches:** Designing mucoadhesive patches involves careful consideration of various factors to ensure effective adhesion to mucosal surfaces and controlled drug delivery. Mucoadhesive patches are transdermal or mucosal delivery systems that adhere to the application site, providing sustained release of drugs or therapeutic agents. Here are the key aspects to consider in the design of mucoadhesive patches:

  - **Mucoadhesive Polymer Selection:** Choosing a suitable mucoadhesive polymer is crucial. Commonly used polymers include chitosan, sodium alginate, hyaluronic acid, and carbopol. The polymer should have the ability to interact with the mucosal surface and provide long-lasting adhesion.
  - **Drug Selection and Loading:** The drug or therapeutic agent to be delivered must be compatible with the mucoadhesive patch system. The drug should have appropriate solubility in the polymer matrix for efficient loading and release.
  - **Patch Matrix Formulation:** The mucoadhesive patch is typically composed of a drug-loaded matrix, which can be a hydrogel or polymer film. The matrix should have the appropriate mechanical strength, flexibility, and biocompatibility.
  - **Mucoadhesive Ligands:** Incorporating specific mucoadhesive ligands, such as lectins or thiolated polymers, can enhance the interaction of the patch with mucosal surfaces, leading to improved adhesion.
  - **Size and Shape:** The size and shape of the mucoadhesive patch should be designed to fit the target mucosal surface. Proper dimensions ensure efficient coverage and contact with the mucosa.
  - **Drug Release Control:** The mucoadhesive patch should be designed to provide controlled drug release. This can be achieved through the choice of polymer, drug loading, and patch thickness.

 

- **Permeation Enhancers:** In some cases, permeation enhancers can be included in the patch formulation to facilitate drug penetration through the mucosal barrier and improve drug absorption.
- **Backing and Protective Layers:** Mucoadhesive patches often include backing layers to protect the patch from external factors and prevent drug loss. Release-controlling membranes may also be used to regulate drug diffusion.
- **Bioadhesion Testing:** Bioadhesion testing is crucial to evaluate the adhesion properties of the patch to mucosal surfaces. In vitro and *in vivo* adhesion tests can provide insights into the patch's mucoadhesive strength.
- **Manufacturing and Packaging:** The manufacturing process should ensure uniform drug distribution and proper quality control. Proper packaging is essential to maintain the stability and integrity of the mucoadhesive patches.[30-33]

Mucoadhesive patches offer a promising approach for localized and targeted drug delivery. Their design should be tailored to the specific drug, application site, and therapeutic goals. Effective mucoadhesive patches can provide improved patient compliance, reduced side effects, and enhanced therapeutic outcomes.

- **Application of Mucoadhesive Patches:** Mucoadhesive patches have various applications in the field of drug delivery and medical treatments. Their ability to adhere to mucosal surfaces makes them valuable for localized and controlled drug release. Some common applications of mucoadhesive patches include:

  - **Oral Drug Delivery:** Mucoadhesive patches can be applied to the buccal mucosa or the inner lining of the cheek for oral drug delivery. They offer improved drug absorption and sustained release, reducing the need for frequent dosing.
  - **Transdermal Drug Delivery:** Mucoadhesive patches can be applied to the skin for transdermal drug delivery. They can adhere to the skin's surface and deliver drugs through the skin, bypassing the gastrointestinal tract and avoiding first-pass metabolism.
  - **Ocular Drug Delivery:** Mucoadhesive patches are used for localized drug delivery to the eye. They can be applied to the conjunctival or corneal surface to provide sustained release of drugs for the treatment of various eye conditions.
  - **Vaginal Drug Delivery:** Mucoadhesive patches are employed for vaginal drug delivery. They can adhere to the vaginal mucosa, delivering drugs directly to the site of action for the treatment of vaginal infections or contraceptive purposes.
  - **Nasal Drug Delivery:** Mucoadhesive patches can be applied to the nasal mucosa for nasal drug delivery. They offer improved drug absorption through the nasal route and can be used for local or systemic drug delivery.
  - **Wound Dressings:** Mucoadhesive patches can be used as wound dressings for localized drug delivery to promote wound healing and prevent infections.
  - **Gastrointestinal Drug Delivery:** Mucoadhesive patches can be applied to the gastrointestinal tract, adhering to the mucosal surfaces and delivering drugs to specific regions of the gastrointestinal system.
  - **Buccal Vaccine Delivery:** Mucoadhesive patches have been investigated as a potential platform for vaccine delivery to the buccal mucosa, offering potential advantages in enhancing immune responses.

 

- **Periodontal Disease Treatment:** Mucoadhesive patches can be used in the treatment of periodontal diseases, delivering drugs locally to the gums and oral tissues.
- **Cancer Therapy:** Mucoadhesive patches have been explored for localized delivery of anticancer drugs to tumours located in mucosal tissues [15, 16].

- **Formulation of Mucoadhesive Films:** The formulation of mucoadhesive films involves several critical considerations to create an effective drug delivery system that adheres to mucosal surfaces and provides controlled drug release. Mucoadhesive films are thin, flexible films that can be applied to various mucosal sites for localized therapy or systemic drug delivery. Here are the key elements to consider in the formulation of mucoadhesive films:

  - **Mucoadhesive Polymer Selection:** Choose a suitable mucoadhesive polymer that exhibits strong interaction with mucosal surfaces. Commonly used mucoadhesive polymers include chitosan, sodium alginate, hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol (PVA), and polycarboPhil. The selection of the mucoadhesive polymer is crucial for ensuring proper adhesion to the target mucosa.
  - **Drug Selection and Loading:** Select the drug or therapeutic agent appropriate for the intended application. Determine the optimal drug loading to achieve the desired therapeutic effect. The drug's physicochemical properties should be compatible with the selected mucoadhesive polymer to ensure uniform distribution within the film matrix [23].
  - **Film Thickness and Size:** Determine the film's thickness and size based on the targeted application and desired drug release profile. The film thickness will influence the drug release kinetics and the residence time on the mucosal surface.
  - **Drug Release Control:** The design of mucoadhesive films should enable controlled drug release over a specific period. The release rate can be controlled by adjusting the polymer type, drug loading, and film thickness.
  - **Formulation Excipients:** Incorporate excipients, such as plasticizers, stabilizers, and release modifiers, to optimize the film's mechanical properties, flexibility, and drug release characteristics.
  - **Mucoadhesive Ligands (Optional):** Consider incorporating mucoadhesive ligands, such as lectins or thiolated polymers, to enhance mucoadhesion and prolong the film's residence time on the mucosal surface.
  - **Bioadhesion Testing:** Conduct bioadhesion testing to evaluate the mucoadhesive strength of the film on mucosal surfaces. *In vitro* and *in vivo* adhesion studies will help assess the film's adhesion properties and ensure proper mucoadhesive behavior.
  - **Manufacturing Method:** Select an appropriate manufacturing method based on the chosen polymer and film formulation. Common fabrication methods include solvent casting, hot melt extrusion, electro spinning, and spray drying.
  - **Stability and Shelf Life:** Ensure that the mucoadhesive films maintain stability and integrity during storage. Conduct stability studies to assess the film's shelf life under various storage conditions.
  - **Targeted Application:** Tailor the design of mucoadhesive films to suit the specific application, such as oral drug delivery, ocular drug delivery, vaginal drug

 

delivery, or gastrointestinal drug delivery. The film's properties should align with the targeted mucosal site and the therapeutic goals [24].

- **Application of Mucoadhesive Films:** Mucoadhesive films have a wide range of applications in the field of drug delivery and medical treatments. Their ability to adhere to mucosal surfaces makes them valuable for localized and controlled drug release. Some common applications of mucoadhesive films include:

  - **Oral Drug Delivery:** Mucoadhesive films can be applied to the buccal or sublingual mucosa for direct drug absorption into the bloodstream, avoiding first-pass metabolism. This route offers rapid drug delivery and prolonged therapeutic effect.
  - **Ocular Drug Delivery:** Mucoadhesive films are used for localized drug delivery to the eye. They can be applied to the conjunctival or corneal surface to provide sustained release of drugs for the treatment of various eye conditions.
  - **Vaginal Drug Delivery:** Mucoadhesive films are applied to the vaginal mucosa for the localized release of drugs. They are used for the treatment of vaginal infections, contraception, or hormone replacement therapy.
  - **Nasal Drug Delivery:** Mucoadhesive films can be applied to the nasal mucosa for nasal drug delivery. They offer improved drug absorption through the nasal route and can be used for local or systemic drug delivery.
  - **Gastrointestinal Drug Delivery:** Mucoadhesive films can be applied to the gastrointestinal tract for targeted drug delivery to specific regions of the gut. They can be used to treat conditions such as inflammatory bowel disease or peptic ulcers.
  - **Wound Dressings:** Mucoadhesive films are used as wound dressings to deliver drugs locally to promote wound healing and prevent infections. They can adhere to the wound surface, providing sustained release of therapeutic agents.
  - **Periodontal Disease Treatment:** Mucoadhesive films can be applied to the gums and oral tissues for localized drug delivery in the treatment of periodontal diseases. They can deliver antimicrobial agents to control infections or growth factors to promote tissue regeneration.
  - **Buccal Vaccine Delivery:** Mucoadhesive films have been investigated as a potential platform for vaccine delivery to the buccal mucosa. They can enhance immune responses and offer an alternative to traditional vaccine administration.
  - **Cancer Therapy:** Mucoadhesive films have been explored for localized delivery of anticancer drugs to tumors located in mucosal tissues, such as oral cancer or cervical cancer.
  - **Transdermal Drug Delivery:** While not strictly a mucosal application, mucoadhesive films can also be applied to the skin for transdermal drug delivery. They can adhere to the skin's surface and deliver drugs through the skin, bypassing the gastrointestinal tract and avoiding first-pass metabolism [25-27]

## 4. Mucoadhesive Implants and Devices

- **Advancement of Mucoadhesive Implants and Devices:** The field of mucoadhesive implants and devices has seen significant advancements. Researchers and Pharmaceutical companies continue to explore and develop new technologies to

 

improve drug delivery and medical treatments using mucoadhesive principles. Some of the advancements in mucoadhesive implants and devices include:

- **Extended Drug Release:** Advances in polymer science and formulation techniques have led to the development of mucoadhesive implants that can provide sustained drug release over an extended period. These implants can deliver drugs locally to mucosal surfaces, offering improved therapeutic outcomes and reduced dosing frequency.
- **Combination Therapies:** Mucoadhesive implants have been explored for combination therapies, where multiple drugs or therapeutic agents are delivered simultaneously to address complex medical conditions. This approach allows for synergistic effects and better disease management.
- **Targeted Drug Delivery:** Researchers are working on enhancing the targeting capabilities of mucoadhesive implants and devices. By incorporating targeting ligands or utilizing stimuli-responsive systems, mucoadhesive implants can deliver drugs specifically to the desired site of action, minimizing off-target effects.
- **Bioresponsive Implants:** Advancements in biomaterials and nanotechnology have enabled the development of bioresponsive mucoadhesive implants. These implants can respond to specific Physiological conditions, such as Ph, enzyme activity, or changes in temperature, triggering drug release when needed.
- **Biodegradable Implants:** Mucoadhesive implants made from biodegradable polymers have gained popularity due to their ability to gradually degrade and be absorbed by the body over time. Biodegradable implants eliminate the need for surgical removal after drug release is complete.
- **Minimally Invasive Delivery:** Research is ongoing to develop mucoadhesive devices that can be delivered via minimally invasive methods, such as injections, sprays, or oral administration. These methods offer patient convenience and reduced procedural risks.
- **Implantable Sensors:** Mucoadhesive implants with integrated sensors have been investigated for real-time monitoring of Physiological parameters or drug release. These smart implants can provide valuable data for personalized medicine and treatment optimization.
- **3D Printing:** Additive manufacturing techniques, such as 3D printing, have been explored for the fabrication of customized mucoadhesive implants. 3D printing allows for precise control over implant design and drug release profiles.
- **Implantable Devices for Chronic Conditions:** Mucoadhesive implants are being developed for the treatment of chronic diseases, such as diabetes, where long-term drug delivery and adherence are crucial for effective management.
- **Clinical Trials:** Many mucoadhesive implants and devices have progressed to preclinical and clinical trials, demonstrating their potential as viable therapeutic options [28-31].

It's important to note that the field of mucoadhesive implants and devices is continually evolving, and there may have been further advancements beyond my last update. Ongoing research and innovation in this area are likely to bring more breakthroughs and new applications of mucoadhesive technology in drug delivery and medical treatments.

- **Challenges of Mucoadhesive Implants and Devices:** While mucoadhesive implants and devices hold great promise for targeted drug delivery and medical treatments, they also face several challenges that need to be addressed for their successful implementation. Some of the key challenges include:

  - **Mucosal Variability:** Mucosal surfaces can vary significantly between individuals and even within the same individual at different times. The effectiveness of mucoadhesive implants may be influenced by the variability in mucosal properties, leading to inconsistent drug delivery and therapeutic outcomes.
  - **Biocompatibility:** Mucoadhesive materials and drug formulations must be biocompatible to avoid irritation, inflammation, or immune responses at the application site. Ensuring the safety of mucoadhesive implants is essential for their clinical use [32].
  - **Mucoadhesive Strength:** Achieving optimal mucoadhesive strength is crucial. Too weak adhesion may result in premature detachment of the implant, while excessively strong adhesion can lead to tissue damage upon removal or affect normal Physiological processes.
  - **Drug Stability:** Some drugs may degrade or lose potency when in contact with the mucoadhesive matrix or mucosal environment. Ensuring drug stability throughout the delivery process is critical for maintaining therapeutic efficacy.
  - **Drug Loading and Release Control:** Controlling drug loading and achieving the desired release kinetics can be challenging. High drug loading may lead to initial burst release, while low loading may result in inadequate therapeutic levels.
  - **Limited Drug Payload:** The size constraints of mucoadhesive implants may limit the amount of drug that can be loaded, which could be a challenge for high-dose or long-term therapies.
  - ***In vivo* Environment:** The *in vivo* environment can affect mucoadhesive performance. Factors such as Ph, enzymes, mucus turnover, and mechanical forces can influence implant adhesion and drug release.
  - **Clearance and Elimination:** Mucoadhesive implants may be subject to clearance mechanisms, leading to their removal from the application site and reducing drug delivery efficiency.
  - **Sterility and Manufacturing:** Ensuring the sterility of mucoadhesive implants during fabrication and handling is critical to prevent infections and adverse reactions.
  - **Regulatory Approval:** The development and commercialization of mucoadhesive implants require rigorous testing and regulatory approval. Meeting safety, efficacy, and quality standards set by regulatory authorities can be time-consuming and costly.
  - **Patient Compliance:** Patient acceptance and adherence to mucoadhesive implants and devices may be influenced by factors such as discomfort, inconvenience, or the need for specialized administration.[33, 34]

## III. MUCOADHESIVE DRUG DELIVERY FOR SPECIFIC APPLICATION

The unique feature of mucoadhesive formulations lies in their ability to adhere to these mucosal tissues for an extended period, enhancing drug residence time and improving

 

drug absorption. This specific application of drug delivery is particularly beneficial in cases where conventional delivery methods may be ineffective or challenging [15]. By utilizing mucoadhesive systems, drugs can achieve sustained and controlled release, leading to improved therapeutic outcomes and reduced dosing frequency. Moreover, mucoadhesive drug delivery offers the advantage of targeted administration, minimizing systemic side effects and enhancing drug efficacy at the desired site of action. This innovative approach holds great promise for optimizing drug delivery in various medical fields, from treating local conditions to improving the bioavailability of drugs with limited absorption through conventional routes [16].

1. **Ophthalmic Drug Delivery:** Ophthalmic drug delivery has been a subject of significant research and development due to the challenges associated with effectively treating ocular diseases. The eye's unique anatomy and Physiology create barriers to drug penetration and retention, limiting the efficacy of traditional eye drops and ointments. Mucoadhesive systems have emerged as a promising advancement in Ophthalmic drug delivery, offering innovative solutions to improve drug residence time, enhance ocular drug absorption, and target specific ocular tissues for the treatment of various eye conditions [35]. Advancements in mucoadhesive systems for ocular diseases have been driven by the need to overcome the challenges associated with traditional Ophthalmic drug delivery methods. The following are some key advancement in mucoadhesive systems for ocular diseases:

    - **Novel Mucoadhesive Polymers:** Researchers have been exploring and developing new mucoadhesive polymers with improved properties, such as enhanced mucoadhesive strength, biocompatibility, and prolonged residence time on the ocular surface. These novel polymers can better adhere to the mucus layer of the eye and promote prolonged drug release, leading to improved drug efficacy and reduced dosing frequency [36].

    - **Nanotechnology and Nanocarriers:** Nanotechnology has been incorporated into mucoadhesive systems to create nanocarriers, such as nanoparticles and liposomes. These nanocarriers can encapsulate drugs, protecting them from degradation and improving their solubility. The use of nanocarriers enhances drug penetration through the ocular barriers, increasing drug bioavailability and targeting specific ocular tissues more effectively.

    - **In Situ Gel-Forming Systems:** In situ gel-forming mucoadhesive systems have gained attention as they can be administered as eye drops but transform into a gel upon contact with the ocular surface. This gel formation prolongs drug contact time, improving drug absorption and reducing the need for frequent dosing. In situ gelling systems also provide ease of administration, enhancing patient compliance.

    - **Ion-Activated Mucoadhesive Systems:** Ion-activated mucoadhesive systems have been designed to take advantage of the ocular Ph changes, which occur upon instillation of eye drops. These systems undergo gelation or mucoadhesion triggered by the change in Ph, leading to enhanced drug retention and sustained release at the ocular surface.

 

- **Combination Therapy:** Mucoadhesive systems have been used to deliver multiple drugs simultaneously, enabling combination therapy for ocular diseases. This approach allows for better management of complex eye conditions, such as inflammation or infection, by delivering synergistic drugs with different mechanisms of action.

- **Contact Lens-Mucoadhesive Hybrid Systems:** Integration of mucoadhesive materials into contact lenses has been explored to create drug-eluting contact lenses. These hybrid systems can release drugs continuously over an extended period, providing sustained drug delivery directly to the eye, and reducing the need for frequent application.

- **Biodegradable Mucoadhesive Implants:** Biodegradable implants that adhere to the ocular surface have been developed to deliver drugs continuously for an extended duration. These implants can be placed in the eye through minimally invasive procedures, offering a long-term treatment option for chronic ocular diseases [37, 38].

2. **Nasal Drug Delivery:** Nasal drug delivery is an attractive and non-invasive route for delivering drugs to the brain directly from the nasal cavity, bypassing the blood-brain barrier. However, the nasal mucosa poses a challenge due to rapid drug clearance by mucociliary clearance and enzymatic degradation. Mucoadhesive formulations have emerged as a promising strategy to enhance nose-to-brain drug delivery by prolonging drug residence time in the nasal cavity and improving drug absorption into the brain [39].

   Mucoadhesive formulations play a crucial role in improving nose-to-brain drug delivery, offering a promising approach to overcome the challenges associated with delivering therapeutics to the brain through the nasal route. These formulations utilize specific polymers or excipients with mucoadhesive properties to adhere to the nasal mucosa, prolonging drug contact time and enhancing drug absorption into the brain [40]. The nasal mucosa presents several barriers to drug delivery, such as rapid mucociliary clearance and enzymatic degradation. Mucoadhesive formulations address these challenges by creating a sustained and localized drug release environment. The mucoadhesive layer formed upon administration traps the drug at the site of absorption, preventing its rapid clearance and degradation. As a result, the drug has a higher chance of reaching the brain through various pathways, including the olfactory and trigeminal nerves [41].

   One of the key advantages of mucoadhesive formulations is their ability to improve drug bioavailability in the brain while reducing systemic exposure and potential side effects. By delivering drugs directly to the brain, mucoadhesive formulations can bypass the blood-brain barrier, which limits the entry of much therapeutics into the central nervous system. This direct delivery to the brain enhances drug efficacy and enables the treatment of neurological disorders more effectively.

   Advancements in nanotechnology have further optimized mucoadhesive formulations for nose-to-brain drug delivery. Nanocarriers, such as nanoparticles or liposome’s, can be integrated into mucoadhesive systems to encapsulate drugs. These nanocarriers protect the drug from enzymatic degradation, facilitate drug release, and

 

improve drug transport across the nasal mucosa, enhancing drug penetration into the brain [42, 43].

Moreover, mucoadhesive formulations offer a non-invasive and patient-friendly approach for delivering drugs to the brain. Compared to invasive methods like intravenous administration or direct brain injections, nasal drug delivery is less traumatic, more convenient, and may improve patient compliance [44].

Despite these advantages, challenges remain in the development of mucoadhesive formulations for nose-to-brain drug delivery. Selecting the appropriate mucoadhesive materials and optimizing the formulation to ensure adequate drug release and stability are critical aspects of successful drug delivery. Additionally, individual variability in nasal anatomy and mucosal properties can impact the performance of these formulations.

3. **Buccal and Sublingual Drug Delivery:** In recent years, mucoadhesive systems for buccal and sublingual drug delivery have witnessed significant advancements, offering improved local and systemic administration of drugs. Mucoadhesive formulations adhere to the oral mucosa, prolonging drug contact time and enhancing drug absorption [45]. Here are some recent developments in mucoadhesive systems for buccal and sublingual drug delivery:

- **Local Drug Delivery**

  - **Controlled Drug Release:** Recent developments have focused on formulating mucoadhesive systems with controlled drug release capabilities. These systems provide sustained drug delivery to the buccal or sublingual mucosa, allowing for targeted treatment of local conditions, such as oral infections, aPhthous ulcers, and mucositis.
  - **Bioadhesive Gels and Sprays:** Novel mucoadhesive gels and sprays have been developed to improve local drug delivery to specific oral tissues. These formulations offer ease of application and prolonged drug retention, making them suitable for topical treatments of oral diseases and dental conditions.
  - **Treatment of Oral Mucosal Disorders:** Advancements in mucoadhesive systems have facilitated the delivery of therapeutic agents for the treatment of oral mucosal disorders, such as lichen planus and oral candidiasis. Mucoadhesive formulations ensure prolonged drug residence at the site of action, improving therapeutic outcomes [46-48].

- **Systemic Drug Delivery**

  - **Nanotechnology-based Mucoadhesive Systems:** Incorporating nanotechnology into mucoadhesive formulations has opened new avenues for systemic drug delivery via the buccal and sublingual routes. Nanocarriers, such as nanoparticles and liposome's, enhance drug stability, penetration, and bioavailability, enabling the delivery of poorly soluble drugs and biologics [49].
  - **Peptide and Protein Delivery:** Recent advancements in mucoadhesive systems have focused on improving the delivery of peptides and proteins through the buccal and sublingual routes. Novel formulations and permeation enhancers have

 

been explored to enhance the absorption of these complex molecules, expanding the potential for non-invasive systemic administration [50].

- **Enhanced Absorption of LipoPhilic Drugs:** Mucoadhesive systems have been designed to improve the absorption of lipoPhilic drugs through the oral mucosa. These formulations address the challenge of delivering lipoPhilic compounds with low oral bioavailability and offer an alternative route for systemic drug administration [51].

- **Pediatric Drug Delivery:** Child-friendly Formulations: Recent developments have emPhasized the formulation of child-friendly mucoadhesive systems, taking into consideration taste, texture, and ease of administration. Pediatric mucoadhesive formulations have been developed to encourage better compliance and acceptance among children [52].

  - **Fever and Pain Relief:** Mucoadhesive systems have been explored for delivering fever and pain relief medications to children through the buccal and sublingual routes, providing an efficient and non-invasive approach for managing common childhood ailments [53].

- **Vaginal Drug Delivery:** Vaginal drug delivery is a specialized approach that has gained attention for its potential to deliver drugs locally to the vaginal mucosa. Mucoadhesive systems have emerged as a promising strategy to enhance drug residence time in the vaginal cavity, improving the effectiveness of treatments and contraceptives.

  Mucoadhesive formulations for vaginal drug delivery utilize specific polymers or excipients with adhesive properties that can adhere to the vaginal mucosa. Upon administration, these formulations form a mucoadhesive layer that adheres to the vaginal epithelium, prolonging drug contact time and facilitating sustained drug release [54]. For effective treatment of vaginal infections, such as bacterial vaginosis or vaginal candidiasis, mucoadhesive systems ensure that the drug remains in close proximity to the infection site, enhancing drug concentration and improving therapeutic outcomes. The prolonged residence time of the drug at the vaginal mucosa allows for higher drug concentrations to be achieved, effectively combating the infection. Mucoadhesive systems have also been explored for the delivery of vaginal contraceptives. The extended drug residence time offered by these formulations enhances the retention of contraceptive agents in the vaginal cavity, improving their contraceptive efficacy. This approach is particularly valuable for long-acting contraceptives, such as vaginal rings, where sustained drug release is essential for effective contraception.

  In addition to improved drug residence time, mucoadhesive systems for vaginal drug delivery offer other advantages, such as reduced systemic side effects and increased patient compliance. By delivering drugs directly to the vaginal mucosa, these formulations minimize the risk of systemic absorption and related side effects. Furthermore, the non-invasive nature of vaginal drug delivery and the ease of administration make it a convenient option for patients, potentially improving adherence to treatment regimens [55].

 

However, challenges remain in the development of mucoadhesive systems for vaginal drug delivery. The selection of suitable mucoadhesive materials, formulation optimization, and safety considerations are crucial aspects that need to be addressed to ensure the effectiveness and safety of these formulations.

Enhancing drug residence time is a critical factor in the effective treatment and contraceptive delivery of vaginal drug delivery using mucoadhesive systems. Mucoadhesive formulations offer several strategies to achieve prolonged drug retention and improve therapeutic outcomes. Some strategies are mentioned below.

- **Mucoadhesive Polymers:** Mucoadhesive systems employ specific polymers with adhesive properties that can interact with the vaginal mucosa. These polymers create a strong bond between the drug-loaded formulation and the mucosal surface, prolonging drug contact time and enhancing drug residence in the vaginal cavity.
- **Gel Formulations:** Mucoadhesive gels have been developed for vaginal drug delivery. These formulations provide a favorable environment for mucoadhesion and sustained drug release. The gel-like consistency enables them to adhere to the vaginal mucosa and gradually release the drug, ensuring prolonged therapeutic levels.
- **Vaginal Rings:** Mucoadhesive vaginal rings are a popular long-acting contraceptive option. These rings contain mucoadhesive agents that adhere to the vaginal wall, allowing slow and continuous drug release over an extended period, often lasting for weeks or months.
- **Nanotechnology:** Incorporating nanotechnology into mucoadhesive systems has further improved drug residence time. Nanocarriers, such as nanoparticles or liposomes, can be used to encapsulate drugs, protect them from degradation, and enhance drug penetration and retention in the vaginal mucosa.
- **pH-Sensitive Formulations:** Some mucoadhesive systems are designed to be pH-sensitive. Upon exposure to the vaginal Ph, these formulations undergo gelation, prolonging drug release and residence time in the vaginal cavity.
- **Bioadhesive Excipients:** The addition of bioadhesive excipients in mucoadhesive formulations enhances drug retention on the vaginal mucosa. These excipients increase the contact area and strengthen the interaction between the drug-loaded formulation and the mucosal surface [55]. By prolonging drug residence time, mucoadhesive systems for vaginal drug delivery offer several advantages.
- **Enhanced Drug Concentration:** Prolonged drug contact with the vaginal mucosa leads to higher drug concentrations at the target site, improving the effectiveness of treatments and contraceptives.
- **Reduced Dosing Frequency:** Longer drug residence time allows for less frequent dosing, improving patient compliance and convenience.
- **Minimized Systemic Side Effects:** By delivering drugs locally, mucoadhesive systems minimize systemic absorption, reducing the risk of systemic side effects.
- **Improved Contraceptive Efficacy:** For contraceptive applications, extended drug residence time ensures sustained and effective contraceptive protection [55, 56].

 

## IV. GASTROINTESTINAL MUCOADHESIVE SYSTEM

Gastrointestinal mucoadhesive systems are specialized drug delivery formulations designed to adhere to the mucosal lining of the gastrointestinal tract. These systems utilize mucoadhesive polymers or compounds that can interact with the mucus layer in the stomach or intestines, prolonging drug contact time and enhancing drug absorption. The goal of gastrointestinal mucoadhesive systems is to improve drug residence time and bioavailability, leading to more effective and targeted drug delivery to treat various gastrointestinal disorders [57].Some key features and applications of gastrointestinal mucoadhesive systems include:

1. **Treatment of Gastrointestinal Disorders:** Gastrointestinal mucoadhesive systems are used to deliver drugs locally to the site of action in the gastrointestinal tract. They are beneficial for the treatment of conditions such as gastric ulcers, inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis), and gastrointestinal infections.

2. **Sustained Drug Release:** Mucoadhesive systems provide sustained drug release, ensuring a continuous supply of the drug to the gastrointestinal mucosa. This sustained release is particularly valuable for chronic conditions where consistent drug levels are needed for effective treatment.

3. **Minimizing Drug Degradation:** By adhering to the mucosal surface, mucoadhesive systems can protect drugs from degradation by enzymes in the gastrointestinal fluids, improving drug stability and bioavailability.

4. **Enhanced Drug Absorption:** The mucoadhesive properties of these formulations improve drug absorption by facilitating drug penetration across the mucus layer and the gastrointestinal epithelium.

5. **Targeted Drug Delivery:** Gastrointestinal mucoadhesive systems can deliver drugs to specific regions of the gastrointestinal tract, providing targeted therapy. For instance, they can be designed to release drugs in the stomach for conditions requiring localized treatment in that area.

6. **Patient Compliance:** These systems may reduce dosing frequency and offer better patient compliance due to the convenience of less frequent administration.

7. **Nanotechnology Advancements:** Incorporating nanotechnology into gastrointestinal mucoadhesive systems has allowed the development of nanocarriers that can encapsulate drugs, further improving drug stability, solubility, and targeted delivery [57, 58].

## V. NOVEL APPROACHES FOR TARGETED THERAPY USING GASTROINTESTINAL MUCOADHESIVE SYSTEM [60, 62, 63, 64].

Novel approaches for targeted therapy using gastrointestinal mucoadhesive systems focus on enhancing the precision and specificity of drug delivery to specific regions or sites within the gastrointestinal tract. These innovative strategies aim to optimize therapeutic outcomes while minimizing off-target effects. Some of the promising novel approaches include:

 

1. **Ligand-Based Targeting:** Ligand-based targeting involves conjugating specific ligands to the surface of mucoadhesive nanoparticles or microparticles. These ligands can selectively bind to receptors or antigens overexpressed on the gastrointestinal mucosa or within diseased tissues. This targeted binding allows for site-specific drug delivery, improving therapeutic efficacy and reducing drug exposure to healthy tissues.

2. **Mucoadhesive Microbots:** Microbots are tiny, self-propelled devices designed to navigate through the gastrointestinal tract. When coated with mucoadhesive materials, these microbots can actively adhere to the gastrointestinal mucosa and deliver drugs directly to the target sites. Controlled propulsion and localization enable precise drug delivery, enhancing therapeutic efficiency.

3. **Mucoadhesive Hydrogel Microneedles:** Microneedles composed of mucoadhesive hydrogel materials can be used to penetrate the gastrointestinal mucosa and deliver drugs directly to the underlying tissues. These microneedles provide a minimally invasive approach for targeted therapy while avoiding the first-pass metabolism associated with oral drug administration.

4. **Magnetic Targeting:** Magnetic nanoparticles incorporated into mucoadhesive formulations can be guided and concentrated to specific regions of the gastrointestinal tract using external magnetic fields. This technique allows for targeted drug delivery to particular sites of interest, such as inflamed regions in inflammatory bowel diseases.

5. **Microbial-Responsive Systems:** Some novel mucoadhesive formulations are designed to respond to specific microbial species or enzymes present in the gastrointestinal environment. These systems can release drugs or therapeutic agents upon contact with certain microbes, providing targeted therapy for conditions associated with dysbiosis or infection.

6. **pH- Responsive Formulations:** pH-responsive mucoadhesive systems release drugs in response to specific pH levels in different regions of the gastrointestinal tract. For example, formulations may release drugs in the acidic environment of the stomach or the alkaline environment of the intestines, allowing for site-specific drug delivery.

7. **Mucoadhesive Patches with Microcontainers:** Patches or films containing microcontainers can be designed to release drugs sequentially or at specific times. This controlled drug release profile enables targeted therapy for time-sensitive conditions or for drugs requiring multiple dosages at different stages of the gastrointestinal tract [59-61]. Novel approaches for sustained release using gastrointestinal mucoadhesive systems aim to extend drug delivery over an extended period, ensuring consistent therapeutic levels and reducing the frequency of dosing. These approaches enhance patient compliance and improve the efficacy of treatments. Some of the promising novel strategies for sustained release include:

    - **Multi-Layered Mucoadhesive Formulations:** Developing mucoadhesive systems with multiple layers can enable a controlled and sustained release of drugs. Different layers can be designed to have varying drug release rates, allowing for sequential release of drugs with different PHarmacokinetic profiles.

 

- **Microsphere-Embedded Mucoadhesive Systems:** Incorporating drug-loaded Microspheres into mucoadhesive formulations can achieve sustained release. The drug is encapsulated within the Microspheres, and the mucoadhesive properties of the system prolong the residence time, leading to sustained drug release as the Microspheres degrade or disintegrate over time.

- **Osmotic Drug Delivery:** Osmotic drug delivery systems consist of a drug core surrounded by a semi permeable membrane with an osmotic agent. When in contact with gastrointestinal fluids, the osmotic agent creates a pressure gradient, leading to controlled drug release over an extended period.

- **Mucoadhesive Implants:** Biodegradable mucoadhesive implants can be placed directly in the gastrointestinal tract during endoscopy or other minimally invasive procedures. These implants gradually release drugs locally over an extended duration, providing sustained therapeutic levels.

- **In Situ Gel-Forming Systems:** Mucoadhesive systems that transform into gels upon contact with gastrointestinal fluids can offer sustained release. The gel formation prolongs the residence time of the drug at the site of action, leading to sustained drug release and absorption.

- **Mucoadhesive Nanoparticles and Liposomes:** Nanocarriers, such as nanoparticles and liposomes, can be designed with mucoadhesive properties to improve drug stability and sustained release. These nanoparticles adhere to the gastrointestinal mucosa, facilitating prolonged drug release and enhanced bioavailability.

- **pH- Sensitive Formulations:** pH-responsive mucoadhesive systems can be designed to release drugs at specific pH levels within the gastrointestinal tract. This approach allows for tailored drug release at different sites, providing sustained release to specific regions. Mucoadhesive Patches or Films: Transdermal patches or films with mucoadhesive properties can be applied to the gastrointestinal mucosa, releasing drugs gradually over time. These systems offer a non-invasive approach for sustained drug delivery.

## VI. REGULATORY CONSIDERATIONS AND CLINICAL TRANSLATION

1. **Regulatory Considerations and Clinical Translation for Mucoadhesive Drug Delivery Systems:** Mucoadhesive drug delivery systems offer significant promise for diverse applications, such as oral, nasal, ocular, and vaginal drug administration. These formulations are designed to adhere to mucosal surfaces, facilitating sustained drug release and close interaction with the intended tissue. Although preclinical research has shown encouraging outcomes, the transition of mucoadhesive systems from the laboratory to clinical practice involves addressing various regulatory hurdles [65]

2. **Regulatory Considerations for Mucoadhesive Drug Delivery Systems**

    - **Preclinical Evaluation:** The initial Phase of clinical translation involves thorough preclinical investigations to evaluate the safety and efficacy of the mucoadhesive

 

drug delivery system. Animal models and *in vitro* tests are employed to study factors such as biocompatibility, adhesion strength, drug release kinetics, and potential mucosal irritation.

- **Biocompatibility and Toxicity:** Regulatory authorities require comprehensive data on the biocompatibility and toxicity of mucoadhesive formulations. It is essential to conduct detailed assessments of any adverse effects on mucosal tissues to ensure patient safety throughout clinical trials[66].

- **Formulation Consistency and Stability:** Stability studies are essential to demonstrate the reproducibility of the mucoadhesive formulation and ensure that the drug's properties remain unchanged over the intended shelf life. These studies are vital to gaining regulatory approval and achieving a commercial product[67].

- **Manufacturing Processes:** A well-defined and controlled manufacturing process is crucial for maintaining consistency and quality of mucoadhesive drug delivery systems. Following Good Manufacturing Practices (GMP) guidelines is essential to ensure compliance with regulatory standards[68].

- ***In Vitro-In Vivo* Correlation (IVIVC):** Establishing a dependable *In Vitro-In Vivo* Correlation (IVIVC) is pivotal in predicting drug behavior in humans based on *in vitro* data. This correlation assists in selecting suitable dosages and provides valuable insights for clinical trials.

## 3. Clinical Translation Challenges

- **Clinical Trial Design:** Designing appropriate clinical trials for mucoadhesive drug delivery systems presents unique challenges due to varying mucosal environments, potential inter-subject variability, and formulation-specific factors. Ensuring sufficient statistical power is essential to draw meaningful conclusions.

- **Pharmacokinetic and Pharmacodynamic Studies:** Understanding drug release, absorption, distribution, metabolism, and elimination kinetics is vital for demonstrating the efficacy of mucoadhesive systems. Additionally, establishing the correlation between drug concentration and therapeutic response is critical.

- **Patient Compliance and Usability:** Regulatory agencies emphasize patient-centric approaches. Therefore, usability studies are essential to assess patient compliance, convenience, and acceptance of mucoadhesive drug delivery systems.

- **Post-Market Surveillance:** Once approved, continuous monitoring of the mucoadhesive product's safety and efficacy becomes crucial. Long-term studies and post-market surveillance are necessary to identify any potential adverse effects that may not have been evident during clinical trials.

## VII. REGULATORY GUIDELINES AND REQUIREMENTS FOR MUCOADHESIVE DRUG DELIVERY SYSTEMS

1. **Regulatory Authorities Involved:** Several regulatory agencies are involved in overseeing the development and approval of mucoadhesive drug delivery systems. The primary agencies include[65]:

   - **Food and Drug Administration (FDA):** United States
   - **European Medicines Agency (EMA):** European Union
   - **Pharmaceuticals and Medical Devices Agency (PMDA):** Japan
   - **World Health Organization (WHO):** Globally, especially for vaccines and essential medicines

2. **Key Regulatory Considerations and Guidelines** [69]**:**

   - **Preclinical Studies**

     - **Biocompatibility and Toxicity Assessment:** Detailed studies to evaluate the safety profile of mucoadhesive formulations on mucosal tissues, including irritation potential and Cytotoxicity.
     - **Pharmacokinetic Studies:** Understanding drug release and distribution in preclinical animal models to establish preliminary evidence of drug absorption and retention.

   - **Good Manufacturing Practices (GMP):** Adherence to GMP guidelines is crucial for the consistent production of mucoadhesive drug delivery systems. This includes standardization of manufacturing processes, equipment, and quality control measures.

   - **Stability Studies:** Detailed stability studies are required to demonstrate that the mucoadhesive formulation maintains its Physical, chemical, and therapeutic integrity over the intended shelf life.

   - ***In Vitro-In Vivo* Correlation (IVIVC):** Establishing an IVIVC is vital to predict drug behavior in humans based on *in vitro* data. This correlation aids in dosage selection and clinical trial design

   - **Clinical Trials**

     - **Design of Clinical Studies:** Well-designed clinical trials are necessary to evaluate the safety, efficacy, and patient compliance of mucoadhesive drug delivery systems.
     - **Pharmacokinetic and Pharmacodynamic Studies:** Understanding drug release kinetics, absorption, distribution, metabolism, and therapeutic response in humans.
     - **Patient Usability:** Assessment of Patient acceptance and ease of use of mucoadhesive drug delivery systems.

- **Quality Control and Batch Testing:** Comprehensive quality control testing is essential to ensure consistency in each batch of the mucoadhesive drug product, complying with regulatory standards.

- **Regulatory Submissions**

  - **Documentation and Data:** Comprehensive submission of preclinical and clinical data, manufacturing processes, stability studies, and safety profiles.
  - **Risk Assessment:** Addressing potential risks associated with the mucoadhesive drug delivery system and providing mitigation strategies.

## 3. Preclinical and Clinical Evaluation of Mucoadhesive Formulations

- **Preclinical Evaluation** [70]

  - **Biocompatibility and Toxicity Studies:** Preclinical investigations involve assessing the biocompatibility of mucoadhesive formulations on mucosal tissues and determining potential toxicity or irritation effects.
  - ***In Vitro* Drug Release Studies:** Understanding the drug release kinetics from mucoadhesive formulations in simulated Physiological conditions.
  - **Pharmacokinetic Studies in Animal Models:** Evaluating the drug absorption, distribution, metabolism, and excretion profiles to predict human Pharmacokinetics.
  - **Adhesion Strength Assessment:** Measuring the adhesive strength of formulations to different mucosal surfaces.
  - **Bioadhesion Mechanism Studies:** Investigating the mechanisms behind the mucoadhesive interactions with mucosal surfaces.

- **Formulation Optimization and Stability**

  - **Formulation Development:** Designing optimized mucoadhesive formulations with enhanced drug retention and release properties.
  - **Stability Studies:** Determining the Physical and chemical stability of the formulation over the intended shelf life under varying storage conditions.

- ***In Vitro-In Vivo* Correlation (IVIVC)**

  - Establishing a reliable IVIVC to predict the *in vivo* behavior of mucoadhesive formulations based on *in vitro* data.
  - Assessing the correlation between *in vitro* drug release profiles and in vivo drug absorption and Pharmacokinetics.

- **Clinical Evaluation**

  - **Phase I Clinical Trials:** Assessing safety, tolerability, and Pharmacokinetics in healthy human volunteers.
  - **Phase II Clinical Trials:** Evaluating the formulation's efficacy and optimal dosing in a small cohort of patients.

 

- **Phase III Clinical Trials:** Conducting large-scale trials to confirm safety and efficacy in a diverse patient population.
- **Comparative Studies:** Comparing the mucoadhesive formulation with conventional formulations or treatment modalities to establish superiority.
- **Patient Compliance and Usability:** Evaluating patient acceptance, ease of use, and compliance with the mucoadhesive formulation.

- **Safety and Adverse Event Monitoring**

  - Monitoring and reporting adverse events during clinical trials.
  - Long-term safety evaluations during post-marketing surveillance.

## VIII. CASE STUDIES AND SUCCESSFUL EXAMPLES OF COMMERCIALIZED MUCOADHESIVE PRODUCTS

The commercialized case studies of mucoadhesive products illustrate the profound influence of these drug delivery systems on modern medicine. Mucoadhesive formulations present distinct benefits, including enhanced drug bioavailability, sustained release, reduced dosing frequency, and improved patient adherence. These successful instances showcase the versatility of mucoadhesive drug delivery systems in diverse therapeutic domains, such as pain management, allergic rhinitis, antifungal therapy, and glaucoma treatment. As ongoing research and development persist in this area, we can anticipate the emergence of more innovative mucoadhesive products, driving further advancements in patient care and treatment effectiveness.

1. **Case Study:** Mucoadhesive Buccal Patch for Pain Management [72].

   - **Product Name:** Fentanyl Buccal Patch
   - **Application:** Treatment of chronic pain in opioid-tolerant patients
   - **Description:** The Fentanyl Buccal Patch is a mucoadhesive transmucosal patch designed for buccal administration. It adheres to the buccal mucosa, providing controlled and continuous delivery of the potent opioid analgesic, fentanyl, over an extended period.
   - **Success Factors:** The buccal route of administration bypasses first-pass metabolism, leading to improved bioavailability and consistent plasma drug levels. The product's convenience and prolonged analgesic effect have contributed to its success in managing chronic pain in selected patient populations.

2. **Case Study:** Mucoadhesive Nasal Spray for Allergic Rhinitis [73].

   - **Product Name:** Fluticasone Nasal Spray
   - **Application:** Management of seasonal and perennial allergic rhinitis
   - **Description:** Fluticasone Nasal Spray is a mucoadhesive intranasal formulation containing the corticosteroid, fluticasone propionate. It adheres to the nasal mucosa, reducing inflammation and providing relief from nasal symptoms associated with allergies.
   - **Success Factors:** The mucoadhesive nasal spray offers prolonged drug contact time at the nasal mucosa, resulting in enhanced drug absorption and local efficacy. Its non-

 

invasive application and once-daily dosing have contributed to its widespread adoption for allergic rhinitis management.

3. **Case Study:** Mucoadhesive Vaginal Gel for Antifungal Therapy [74].

- **Product Name:** Clotrimazole Vaginal Gel
- **Application:** Treatment of vaginal yeast infections (vulvovaginal candidiasis)
- **Description:** Clotrimazole Vaginal Gel is a mucoadhesive hydrogel formulation containing the antifungal agent, clotrimazole. It adheres to the vaginal mucosa, providing sustained drug release and effective treatment of fungal infections.
- **Success Factors:** The mucoadhesive gel ensures localized drug delivery, minimizing systemic exposure and reducing the risk of adverse effects. Its user-friendly applicator and patient convenience have contributed to its success as a first-line treatment for vaginal yeast infections.

4. **Case Study:** Mucoadhesive Ophthalmic Solution for Glaucoma Treatment [75].

- **Product Name:** Timolol Ophthalmic Gel-forming Solution
- **Application:** Management of intraocular pressure in glaucoma patients
- **Description:** Timolol Ophthalmic Gel-forming Solution is a mucoadhesive eye drop formulation containing the beta-blocker, timolol. It adheres to the ocular surface, providing sustained drug release and reducing intraocular pressure in glaucoma patients.
- **Success Factors:** The mucoadhesive formulation increases ocular residence time, enhancing drug absorption and improving therapeutic efficacy. The once-daily dosing regimen and reduced systemic side effects have contributed to its commercial success in glaucoma management.

## IX. FUTURE DIRECTIONS AND POTENTIAL APPLICATIONS IN PERSONALIZED MEDICINE AND TARGETED THERAPIES

Personalized medicine aims to tailor medical treatment to individual patients based on their unique genetic makeup, lifestyle, and enhancing therapeutic efficacy. Mucoadhesive drug delivery systems, with their ability to adhere to mucosal surfaces and release drugs in a controlled manner, present an exciting opportunity for advancing personalized medicine and targeted therapies[76].

1. **Precision Targeting and Site-Specific Delivery:** Mucoadhesive formulations offer precise targeting of drugs to specific mucosal tissues, enabling localized treatment for various conditions. In the respiratory system, targeted delivery of anti-inflammatory agents can alleviate symptoms of diseases like asthma and chronic obstructive pulmonary disease (COPD). In the gastrointestinal tract, mucoadhesive drug delivery can be employed for site-specific treatment of inflammatory bowel diseases (IBD) and gastrointestinal infections. Similarly, for vaginal and ocular conditions, mucoadhesive products provide effective drug delivery and sustained therapeutic effects [77].

2. **Personalized Dosing and Drug Release:** The Pharmacokinetics of drugs can vary significantly among individuals due to genetic variations and Physiological factors.

 

Mucoadhesive drug delivery allows for customized dosing and release profiles, tailoring treatment to an individual's specific needs. By optimizing drug release rates and absorption, mucoadhesive formulations can achieve better therapeutic outcomes and minimize adverse effects [78].

3. **Combination Therapies and Synergistic Effects:** Mucoadhesive drug delivery systems enable the co-administration of multiple drugs, facilitating combination therapies. The simultaneous delivery of drugs with complementary mechanisms of action can enhance treatment efficacy, especially in cancer therapy, where combination regimens can target multiple pathways and reduce the risk of drug resistance [79].

4. **Immunomodulation and Vaccination:** Mucosal surfaces represent key sites of immune activity, making them attractive targets for immunomodulatory therapies and vaccines. Mucoadhesive drug delivery can enhance the effectiveness of immunotherapies, promoting immune responses at specific mucosal sites. In the context of vaccination, mucoadhesive formulations can deliver antigens to mucosal tissues, inducing both systemic and mucosal immunity, which is particularly relevant for preventing infections at the site of entry [80].

5. **Therapeutics and Monitoring:** Mucoadhesive nanoparticles and hydrogels can be engineered to carry both therapeutic agents and imaging agents, creating theranostic platforms. These systems enable simultaneous therapy and diagnosis, providing real-time monitoring of treatment response and disease progression. Theranostic mucoadhesive formulations offer a new paradigm for personalized treatment and precision medicine [81].

6. **Mucoadhesive Bioelectronics:** The integration of electronic components into mucoadhesive drug delivery systems opens up new possibilities for personalized medicine. Bioelectronics can provide real-time data on drug release, patient responses, and Physiological changes, allowing for adaptive dosing and personalized therapy adjustments.

## X. CHALLENGES AND CONSIDERATIONS

Despite the promising potential of mucoadhesive drug delivery in personalized medicine, several challenges need to be addressed. These include maintaining formulation stability, optimizing mucoadhesive properties, ensuring biocompatibility, and developing robust manufacturing processes to ensure reproducibility and scalability [66]. Mucoadhesive drug delivery systems hold great promise for the future of personalized medicine and targeted therapies. The ability to achieve precise targeting, personalized dosing, and combination therapies through mucoadhesive formulations offers significant benefits for patients and healthcare providers. Continued research and technological advancements in this domain will drive the realization of personalized treatment regimens and revolutionize the field of precision medicine, ultimately leading to improved patient outcomes and enhanced quality of life.

 

## XI. CONCLUSION

In conclusion, the recent advancements in the mucoadhesive drug delivery domain have brought about significant improvements in drug delivery strategies, revolutionizing the way medications are administered. Mucoadhesive systems have proven to be highly effective in enhancing drug bioavailability, prolonging drug residence time, and targeting specific sites of action, resulting in improved therapeutic outcomes and patient compliance. The development of novel mucoadhesive polymers and nanoparticles has expanded the scope of drug delivery possibilities, allowing for the controlled and sustained release of various drugs across different mucosal surfaces. These innovations have opened up new opportunities for delivering a wide range of therapeutics, including vaccines, proteins, peptides, and nucleic acids. Furthermore, the integration of advanced nanotechnology and bioengineering techniques has enabled the creation of mucoadhesive platforms with improved stability, biocompatibility, and tailored release profiles, making them ideal candidates for various therapeutic applications. Moreover, the successful translation of mucoadhesive drug delivery systems from preclinical research to clinical trials showcases their potential for real-world applications. These advancements have contributed to reducing the frequency of drug administrations, minimizing side effects, and ultimately enhancing patient adherence to treatment regimens. However, challenges such as the optimization of mucoadhesive formulations, understanding the long-term safety profile, and scalability for large-scale production remain areas of ongoing research. Continued interdisciplinary efforts among researchers, clinicians, and Pharmaceuticals industries will be essential to address these challenges and fully unlock the potential of mucoadhesive drug delivery in improving patient health outcomes. Overall, the remarkable progress in the mucoadhesive drug delivery domain holds great promise for the future of medicine, providing a platform for more effective and patient-friendly therapies, and paving the way for personalized and targeted treatments in diverse healthcare settings. As the field continues to evolve, we can anticipate even more groundbreaking discoveries and advancements that will further revolutionize drug delivery and patient care.

## REFERENCES

[1] Pandey, M., Choudhury, H., Shao Ying, J. N., Sze Ling, J. F., Ting, J., Szhiou Ting, J. S., Zhia Hwen, I. K., Suen, H. W., Samsul Kamar, H. S., Gorain, B., Jain, N., & Iqbal Mohd Amin, M. C. Mucoadhesive Nanocarriers as a Promising Strategy to Enhance Intracellular Delivery against Oral Cavity Carcinoma. PHarmaceutics, 2022, 14(4).

[2] Boddupalli, B. M., K. Mohammed, Z. N., Nath, R. A., & Banji, D. Mucoadhesive drug delivery system: An overview. Journal of Advanced PHarmaceutical Technology & Research, 2011, 1(4), 381-387.

[3] Jawadi, Z., Yang, C., Haidar, Z. S., Santa Maria, P. L., & Massa, S. Bio-Inspired Muco-Adhesive Polymers for Drug Delivery Applications. Polymers, 2022, 14(24), 5459.

[4] Gilhotra, R. M., Ikram, M., Srivastava, S., & Gilhotra, N. A clinical perspective on mucoadhesive buccal drug delivery systems. Journal of Biomedical Research, 2014, 28(2), 81-97.

[5] Wen, H., Jung, H., & Li, X. Drug Delivery Approaches in Addressing Clinical PHarmacology-Related Issues: Opportunities and Challenges. The AAPS Journal, 2015, 17(6), 1327-1340.

[6] Reddy, P. C., Chaitanya, S. C., & Rao, Y. M. A review on bioadhesive buccal drug delivery systems: Current status of formulation and evaluation methods. DARU Journal of PHarmaceutical Sciences, 2011, 19(6), 385-403

[7] Kumar, R., Islam, T., & Nurunnabi, M. Mucoadhesive carriers for oral drug delivery. Journal of controlled release: Official journal of the Controlled Release Society, 2022, 351, 504.

[8] Shaikh, R., Raj Singh, T. R., Garland, M. J., Woolfson, A. D., & Donnelly, R. F. Mucoadhesive drug delivery systems. Journal of PHarmacy and Bioallied Sciences, 2011, 3(1), 89-100.

[9] Shaikh, R., Raj Singh, T. R., Garland, M. J., Woolfson, A. D., & Donnelly, R. F. Mucoadhesive drug delivery systems. Journal of PHarmacy and Bioallied Sciences, 2011, 3(1), 89-100.

 

[10] Gilhotra, R. M., Ikram, M., Srivastava, S., & Gilhotra, N. A clinical perspective on mucoadhesive buccal drug delivery systems. Journal of Biomedical Research, 2014, 28(2), 81-97.
[11] Erjavec, Vladimira & Pavlica, Zlatko & Sentjurc, Marjeta & Petelin, Milan. *In vivo* study of liposomes as drug carriers to oral mucosa using EPR oximetry. International journal of Pharmaceutics. 2006, 307. 1-8.
[12] Chai Q, Jiao Y, Yu X. Hydrogels for biomedical applications: their characteristics and the mechanisms behind them. Gels. 2017 Jan 24;3(1):6.
[13] Tabata Y. Biomaterial technology for tissue engineering applications. J R Soc Interf 2009;6:S311–24.
[14] Shantha KL, Harding DRK. Synthesis and evaluation of sucrose-containing polymeric hydrogels for oral drug delivery. J Appl Polym Sci 2002;84:2597.
[15] 16. Shaikh R, Singh TR, Garland MJ, Woolfson AD, Donnelly RF. Mucoadhesive drug delivery systems. Journal of Pharmacy and Bioallied Sciences. 2011 Jan;3(1):89.
[16] 17. Boddupalli BM, Mohammed ZN, Nath RA, Banji D. Mucoadhesive drug delivery system: An overview. Journal of advanced Pharmaceutical technology & research. 2010 Oct;1(4):381.
[17] Caramella CM, Rossi S, Ferrari F, Bonferoni MC, Sandri G. Mucoadhesive and thermogelling systems for vaginal drug delivery. Advanced drug delivery reviews. 2015 Sep 15;92:39-52.
[18] Caló E, Khutoryanskiy VV. Biomedical applications of hydrogels: A review of patents and commercial products. European polymer journal. 2015 Apr 1;65:252-67.
[19] das Neves J, Amiji M, Sarmento B. Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2011 Jul;3(4):389-99.
[20] Patil SB, Sawant KK. Mucoadhesive Microspheres: a promising tool in drug delivery. Current drug delivery. 2008 Oct 1;5(4):312-8.
[21] Park CG, Kim MJ, Park M, Choi SY, Lee SH, Lee JE, Shin GS, Park KH, Choy YB. Nanostructured mucoadhesive microparticles for enhanced preocular retention. Acta biomaterialia. 2014 Jan 1;10(1):77-86.
[22] Park CG, Kim YK, Kim MJ, Park M, Kim MH, Lee SH, Choi SY, Lee WS, Chung YJ, Jung YE, Park KH. Mucoadhesive microparticles with a nanostructured surface for enhanced bioavailability of glaucoma drug. Journal of Controlled Release. 2015 Dec 28;220:180-8.
[23] Morales JO, McConville JT. Manufacture and characterization of mucoadhesive buccal films. European Journal of PHarmaceutics and BioPharmaceutics. 2011 Feb 1;77(2):187-99.
[24] Mukhopadhyay R, Gain S, Verma S, Singh B, Vyas M, Mehta M. Polymers in designing the mucoadhesive films: A comprehensive review. International Journal of Green PHarmacy. 2018 Apr 1;12(2):S330-44.
[25] Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Advanced drug delivery reviews. 2005 Nov 3;57(11):1595-639.
[26] Neves JD, Palmeira-de-Oliveira R, Palmeira-de-Oliveira A, Rodrigues F, Sarmento B. Vaginal mucosa and drug delivery. Mucoadhesive materials and drug delivery systems. 2014 May 2:99-132.
[27] Gupta P. An overview of applications of mucoadhesive buccal film in Oral Medicine. Journal of Orofacial Research. 2020:14-9.
[28] Bayer IS. Recent advances in mucoadhesive interface materials, mucoadhesion characterization, and technologies. Advanced Materials Interfaces. 2022 Jun;9(18):2200211.
[29] Kompella UB, Kadam RS, Lee VH. Recent advances in Ophthalmic drug delivery. Therapeutic delivery. 2010 Sep;1(3):435-56.
[30] Duggan S, Cummins W, O'Donovan O, Hughes H, Owens E. Thiolated polymers as mucoadhesive drug delivery systems. European Journal of PHarmaceutical Sciences. 2017 Mar 30;100:64-78.
[31] Sharifianjazi F, Khaksar S, Esmaeilkhanian A, Bazli L, Eskandarinezhad S, Salahshour P, Sadeghi F, Rostamnia S, Vahdat SM. Advancements in fabrication and application of chitosan composites in implants and dentistry: A review. Biomolecules. 2022 Jan 18;12(2):155.
[32] Kar A, Ahamad N, Dewani M, Awasthi L, Patil R, Banerjee R. Wearable and implantable devices for drug delivery: Applications and challenges. Biomaterials. 2022 Apr 1;283:121435.
[33] Edmans JG, Clitherow KH, Murdoch C, Hatton PV, Spain SG, Colley HE. Mucoadhesive electrospun fibre-based technologies for oral medicine. PHarmaceutics. 2020 Jun 2;12(6):504.
[34] Yellepeddi VK, Sheshala R, McMillan H, Gujral C, Jones D, Singh TR. Punctal plug: a medical device to treat dry eye syndrome and for sustained drug delivery to the eye. Drug discovery today. 2015 Jul 1;20(7):884-9.
[35] Bayer IS. Recent advances in mucoadhesive interface materials, mucoadhesion characterization, and technologies. Advanced Materials Interfaces. 2022 Jun;9(18):2200211.

 

[36] Dave RS, Goostrey TC, Ziolkowska M, Czerny-Holownia S, Hoare T, Sheardown H. Ocular drug delivery to the anterior segment using nanocarriers: A mucoadhesive/mucopenetrative perspective. Journal of Controlled Release. 2021 Aug 10;336:71-88.
[37] Kompella UB, Kadam RS, Lee VH. Recent advances in Ophthalmic drug delivery. Therapeutic delivery. 2010 Sep;1(3):435-56.
[38] Achouri D, Alhanout K, Piccerelle P, Andrieu V. Recent advances in ocular drug delivery. Drug development and industrial Pharmacy. 2013 Nov 1;39(11):1599-617.
[39] Warnken ZN, Smyth HD, Watts AB, Weitman S, Kuhn JG, Williams III RO. Formulation and device design to increase nose to brain drug delivery. Journal of Drug Delivery Science and Technology. 2016 Oct 1;35:213-22.
[40] Porfiryeva NN, Semina II, Salakhov IA, Moustafine RI, Khutoryanskiy VV. Mucoadhesive and mucus-penetrating interpolyelectrolyte complexes for nose-to-brain drug delivery. Nanomedicine: Nanotechnology, Biology and Medicine. 2021 Oct 1;37:102432.
[41] Fonseca FN, Betti AH, Carvalho FC, Gremião MP, Dimer FA, Guterres SS, Tebaldi ML, Rates SM, Pohlmann AR. Mucoadhesive amPhiPhilic methacrylic copolymer-functionalized poly (ε-caprolactone) nanocapsules for nose-to-brain delivery of olanzapine. Journal of biomedical nanotechnology. 2015 Aug 1;11(8):1472-81.
[42] Emad NA, Ahmed B, Alhalmi A, Alzobaidi N, Al-Kubati SS. Recent progress in nanocarriers for direct nose to brain drug delivery. Journal of Drug Delivery Science and Technology. 2021 Aug 1;64:102642.
[43] Rassu G, Soddu E, Cossu M, Gavini E, Giunchedi P, Dalpiaz A. Particulate formulations based on chitosan for nose-to-brain delivery of drugs. A review. Journal of Drug Delivery Science and Technology. 2016 Apr 1;32:77-87.60.
[44] Formica ML, Real DA, Picchio ML, Catlin E, Donnelly RF, Paredes AJ. On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles. Applied Materials Today. 2022 Dec 1;29:101631.
[45] Gilhotra RM, Ikram M, Srivastava S, Gilhotra N. A clinical perspective on mucoadhesive buccal drug delivery systems. Journal of biomedical research. 2014 Mar;28(2):81.
[46] Hearnden V, Sankar V, Hull K, Juras DV, Greenberg M, Kerr AR, Lockhart PB, Patton LL, Porter S, Thornhill MH. New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Advanced drug delivery reviews. 2012 Jan 1;64(1):16-28.
[47] Hearnden V, Sankar V, Hull K, Juras DV, Greenberg M, Kerr AR, Lockhart PB, Patton LL, Porter S, Thornhill MH. New developments and opportunities in oral mucosal drug delivery for local and systemic disease. Advanced drug delivery reviews. 2012 Jan 1;64(1):16-28.
[48] Salamat-Miller N, Chittchang M, Johnston TP. The use of mucoadhesive polymers in buccal drug delivery. Advanced drug delivery reviews. 2005 Nov 3;57(11):1666-91.
[49] Patra JK, Das G, Fraceto LF, Campos EV, Rodriguez-Torres MD, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S. Nano based drug delivery systems: recent developments and future prospects. Journal of nanobiotechnology. 2018 Dec;16(1):1-33.
[50] Caon T, Jin L, Simões CM, Norton RS, Nicolazzo JA. Enhancing the buccal mucosal delivery of peptide and protein therapeutics. PHarmaceutical research. 2015 Jan;32:1-21.
[51] Madhav NS, Shakya AK, Shakya P, Singh K. Orotransmucosal drug delivery systems: a review. Journal of controlled release. 2009 Nov 16;140(1):2-11.
[52] Yir-Erong B, Bayor MT, Ayensu I, Gbedema SY, Boateng JS. Oral thin films as a remedy for noncompliance in pediatric and geriatric patients. Therapeutic delivery. 2019 Jun;10(7):443-64.
[53] Lam JK, Cheung CC, Chow MY, Harrop E, Lapwood S, Barclay SI, Wong IC. Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic. Advanced Drug Delivery Reviews. 2020 Jan 1;160:234-43.
[54] Valenta C. The use of mucoadhesive polymers in vaginal delivery. Advanced drug delivery reviews. 2005 Nov 3;57(11):1692-712.
[55] Baloglu E, Bernkop-Schnürch A, Karavana SY, Senyigit ZA. Strategies to prolong the intravaginal residence time of drug delivery systems. Journal of PHarmacy & PHarmaceutical Sciences. 2009 Oct 13;12(3):312-36.
[56] TUĞCU-DEMİRÖZ F. Development of in situ poloxamer-chitosan hydrogels for vaginal drug delivery of benzydamine hydrochloride: Textural, mucoadhesive and *in vitro* release properties. Marmara Pharmaceutical journal. 2017 Jan 1;21(4):762-70.
[57] Rathee P, Jain M, Garg A, Nanda A, Hooda A. Gastrointestinal mucoadhesive drug delivery system: A review. J PHarm Res. 2011 May;4(5):1488-53.

 

[58] Varum FJ, McConnell EL, Sousa JJ, Veiga F, Basit AW. Mucoadhesion and the gastrointestinal tract. Critical Reviews™ in Therapeutic Drug Carrier Systems. 2008;25(3).
[59] Khan AB, Mahamana R, Pal E. Review on mucoadhesive drug delivery system: novel approaches in modern era. RGUHS J PHarm Sci. 2014 Oct;4(4):128-41.
[60] Lohani A, Chaudhary G. Mucoadhesive Microspheres: A novel approach to increase gastroretention. Chronicles of Young Scientists. 2012 Apr 1;3(2):121-.
[61] Gavini V, Ragini B, Kaumudi K, Hills V. Mucoadhesive Microspheres-a novel approach of drug targeting. World J PHarm PHarm Sci. 2014 Jul 25;3(10):310-5.
[62] Chavanpatil MD, Jain P, Chaudhari S, Shear R, Vavia PR. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. International journal of Pharmaceutics. 2006 Jun 19;316(1-2):86-92.
[63] Liu H, Pan W, Ke P, Dong Y, Ji L. Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir Microsphere. Drug development and industrial Pharmacy. 2010 Sep 1;36(9):1098-105.
[64] Dhaneshwar P, StePhen P, Rajalakshmi AN. Sustained release effervescent floating bilayer tablets-A review of Novel Approach. PHarmaTutor. 2017 Aug 1;5 (8):32-40.
[65] Boddupalli B, Mohammed Z., Nath R, Banji D. Mucoadhesive drug delivery system: An overview. J Adv PHarm Technol Res. 2010;1(4):381.
[66] Kumar R, Islam T, Nurunnabi M. Mucoadhesive carriers for oral drug delivery. J Control Release. 2022 Nov;351:504–59.
[67] Ghazwani M, Vasudevan R, Kandasamy G, Manusri N, Devanandan P, Puvvada RC, et al. Formulation of Intranasal Mucoadhesive Thermotriggered In Situ Gel Containing Mirtazapine as an Antidepressant Drug. Gels. 2023 Jun 2;9(6):457.
[68] Souto EB, Silva GF, Dias-Ferreira J, Zielinska A, Ventura F, Durazzo A, et al. NanoPharmaceutics: Part I—Clinical Trials Legislation and Good Manufacturing Practices (GMP) of Nanotherapeutics in the EU. PHarmaceutics. 2020 Feb 11;12(2):146.
[69] Zhu W, Chuah YJ, Wang D-A. Bioadhesives for internal medical applications: A review. Acta Biomater. 2018 Jul;74:1–16.
[70] Colombo M, Figueiró F, de Fraga Dias A, Teixeira HF, Battastini AMO, Koester LS. Kaempferol-loaded mucoadhesive nanoemulsion for intranasal administration reduces glioma growth in vitro. Int J PHarm . 2018 May;543(1–2):214–23.
[71] de Lima CSA, Varca JPRO, Alves VM, Nogueira KM, Cruz CPC, Rial-Hermida MI, et al. Mucoadhesive Polymers and Their Applications in Drug Delivery Systems for the Treatment of Bladder Cancer. Gels. 2022 Sep 15;8(9):587.
[72] Fine PG, Narayana A, Passik SD. Treatment of Breakthrough Pain with Fentanyl Buccal Tablet in Opioid-Tolerant Patients with Chronic Pain: Appropriate Patient Selection and Management. Pain Med. 2010 Jul 1;11(7):1024–36.
[73] Valerieva A, Popov TA, Staevska M, Kralimarkova T, Petkova E, Valerieva E, et al. Effect of micronized cellulose powder on the efficacy of topical oxymetazoline in allergic rhinitis. Allergy Asthma Proc. 2015 Nov 1;36(6):134–9.
[74] Valamla B, Thakor P, PHuse R, Dalvi M, Kharat P, Kumar A, et al. Engineering drug delivery systems to overcome the vaginal mucosal barrier: Current understanding and research agenda of mucoadhesive formulations of vaginal delivery. J Drug Deliv Sci Technol. 2022 Apr;70:103162.
[75] Jumelle C, Gholizadeh S, Annabi N, Dana R. Advances and limitations of drug delivery systems formulated as eye drops. J Control Release. 2020 May;321:1–22.
[76] Subramanian P. Mucoadhesive Delivery System: A Smart Way to Improve Bioavailability of Nutraceuticals. Foods. 2021 Jun 11;10(6):1362.
[77] Mishra B, Singh J. Novel drug delivery systems and significance in respiratory diseases. In: Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems. Elsevier; 2020. p. 57–95.
[78] Karavasili C, Eleftheriadis GK, Gioumouxouzis C, Andriotis EG, Fatouros DG. Mucosal drug delivery and 3D printing technologies: A focus on special patient populations. Adv Drug Deliv Rev. 2021 Sep;176:113858.
[79] Pandey M, Choudhury H, Ying JNS, Ling JFS, Ting J, Ting JSS, et al. Mucoadhesive Nanocarriers as a Promising Strategy to Enhance Intracellular Delivery against Oral Cavity Carcinoma. PHarmaceutics. 2022 Apr 5;14(4):795.
[80] Cho C-S, Hwang S-K, Gu M-J, Kim C-G, Kim S-K, Ju D-B, et al. Mucosal Vaccine Delivery Using Mucoadhesive Polymer Particulate Systems. Tissue Eng Regen Med. 2021 Oct 25;18(5):693–712.
[81] Liu R, Luo C, Pang Z, Zhang J, Ruan S, Wu M, et al. Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. Chinese Chem Lett. 2023 Feb;34(2):107518.

 